Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Database
Publication year range
1.
Climacteric ; 26(3): 284-288, 2023 06.
Article in English | MEDLINE | ID: mdl-36912363

ABSTRACT

OBJECTIVE: Overactive bladder (OAB) is a complex and multifactorial syndrome associated with urinary frequency, urgency and incontinence. The menopause-associated hormonal changes play a role in the development of this condition. Vaginal estrogens are effective in improving OAB in postmenopausal women (PMW) with vulvovaginal atrophy (VVA). Ospemifene is a selective estrogen receptor modulator licensed for the treatment of VVA. This study aimed to evaluate the effects of ospemifene on OAB symptoms in PMW with VVA. METHODS: Forty PMW suffering from OAB and VVA received oral ospemifene (60 mg/day) for 12 weeks. All patients were assessed with a urodynamic study, a 3-day bladder diary and validated questionnaires (International Consultation on Incontinence Questionnaire - Urinary Incontinence Short Form [ICIQ-UI SF] and International Consultation on Incontinence Questionnaire - Overactive Bladder [ICIQ-OAB]) at enrollment and at the end of the study. RESULTS: Cytometric capacity, bladder compliance and verbal sensory threshold responses during bladder filling were improved after treatment. The voiding diary showed a significant reduction of daily voids, urge urinary incontinence episodes and nocturnal events. The median overall scores of the ICIQ-UI and ICIQ-OAB were also significantly improved. CONCLUSIONS: Our study suggest that treatment with ospemifene in PMW suffering from OAB is associated with a reduction of OAB symptoms due to a decreased bladder sensitivity and with an improvement in quality of life.


Subject(s)
Urinary Bladder, Overactive , Urinary Incontinence , Humans , Female , Urinary Bladder, Overactive/drug therapy , Postmenopause , Quality of Life , Urinary Incontinence/drug therapy , Atrophy/drug therapy , Treatment Outcome
2.
Climacteric ; 24(6): 531-532, 2021 12.
Article in English | MEDLINE | ID: mdl-34169785

ABSTRACT

The management of pelvic organ disorders is common and challenging work. Nowadays, midlife women are more active than they were in the past, and the development of pelvic organ prolapse (POP) disrupts quality of life and impairs social and personal activities. The aging process and hormonal changes have a role in influencing the structure and function of the lower urinary and genital tract. Correct diagnosis of pelvic organ disorders and the identification of women's symptoms are the hallmarks of tailored management. Treatment is multimodal and multidisciplinary; it requires competence in pelvic medicine and surgery. When conservative treatments fail, women with symptomatic POP are candidates for reconstructive surgery: the optimal management requires clinicians who are familiar with all of the available strategies and who are able to choose the best strategies in a tailored manner. Knowing and understanding the management of POP should be integrated into the practice of health-care professionals dealing in menopause.


Subject(s)
Menopause , Pelvic Floor , Quality of Life , Aging , Humans
3.
Med Hypotheses ; 50(3): 253-7, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9578330

ABSTRACT

Both human cell lines HL-60 and AML-193 exhibit a myeloblastic and promyelocytic morphology, respectively, but may be regarded as bipotent leukemic precursors. They can be triggered to differentiate to either granulocytes or monocytes upon retinoic acid (RA) or 1,25-dihydroxyvitamin D (D3) addition, respectively. We have investigated the effect of combined addition of these chemical inducers on the in-vitro differentiation of both cell lines. RA and D3 added together exert synergistic effects on the in-vitro maturation of these myeloid cell lines. Interestingly, the additive effects were lost if the cells were incubated with the inducers added at sequential times. The synergistic effect could be transposed in vivo and could be clinically significant in the treatment of the promyelocytic leukemia. This clinical strategy may help to prevent retinoic acid resistance or to overcome it in patients relapsed after RA therapy and usually unresponsive to a reinduction therapy with RA alone.


Subject(s)
Cholecalciferol/administration & dosage , Leukemia, Promyelocytic, Acute/drug therapy , Tretinoin/administration & dosage , Cell Differentiation/drug effects , Drug Resistance , Drug Synergism , HL-60 Cells , Humans , Leukemia, Promyelocytic, Acute/pathology , Models, Biological , Tumor Cells, Cultured
4.
Am J Med Sci ; 315(1): 59-62, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9427577

ABSTRACT

A marked discrepancy between mild and late clinical features and a nearly complete absence of erythrocyte uroporphyrinogen decarboxylase activity (Ery-UROD activity) was observed in a case of inherited porphyria cutanea tarda. The entity and time of appearance of clinical features, the onset of clinical symptoms after exposure to contributing factors, the effectiveness of phlebotomies and heterozygosity of the mother alone for uroporphyrinogen decarboxylase (UROD) deficiency were typical for familial porphyria cutanea tarda (F-PCT), whereas the extremely low UROD activity was peculiar to hepatoerythropoietic porphyria (HEP). These observations indicate that: 1) Ery-UROD activity may not always be useful to discriminate between F-PCT and HEP; 2) Ery-UROD activity does not always correlate with clinical symptoms; 3) in inherited UROD deficiency, the genetic defect may be heterogeneous. Finally, the observed discrepancy may provide additional evidence for the existence of tissue-specific isozymes.


Subject(s)
Erythrocytes/enzymology , Porphyria Cutanea Tarda/diagnosis , Porphyria Cutanea Tarda/genetics , Uroporphyrinogen Decarboxylase/blood , Adult , Biomarkers/blood , Consanguinity , Diagnosis, Differential , Female , Humans , Male , Pedigree , Porphyria Cutanea Tarda/therapy , Porphyrins/blood , Porphyrins/urine
5.
Ann Ital Chir ; 64(3): 271-4, 1993.
Article in Italian | MEDLINE | ID: mdl-8109813

ABSTRACT

After thyroidectomy, either total or partial, hypocalcaemia can occur in some cases temporary and in other permanent. For explaining transient hypocalcaemia are reported some pathogenetic mechanism can assume particular aspects in hyperthyroid subjects. Permanent hypocalcaemia is substantially due to anatomical lesions to the parathyroid glands. On the other hand, in subjects with hypothyroidism postoperative, a reduced concentration of circulating calcium can coexist with normal values or even elevated of parathormone. The condition of euthyroidism is basic for the resumption of the calcium homoeostasis.


Subject(s)
Hypocalcemia/etiology , Postoperative Complications/etiology , Thyroidectomy/adverse effects , Humans , Hyperthyroidism/complications , Hyperthyroidism/surgery , Hypoparathyroidism/complications
SELECTION OF CITATIONS
SEARCH DETAIL